Monthly Cost Analysis: Wegovy vs Mounjaro Investment
1.7mg Wegovy to Mounjaro Monthly Cost: Understanding Your Options
The transition from 1.7mg Wegovy to Mounjaro consideration represents a critical decision point in your weight management journey, particularly regarding ongoing monthly investment. Wegovy 1.7mg costs £139.99 monthly during weeks 13-16, representing the penultimate dose before reaching 2.4mg maintenance at £209.99 monthly. Mounjaro's equivalent stage varies significantly, as tirzepatide follows a different escalation schedule with 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg options. The monthly cost comparison between 1.7mg Wegovy to Mounjaro depends entirely on which Mounjaro dose provides comparable efficacy for your individual response.
When evaluating 1.7mg Wegovy to Mounjaro monthly costs, consider that you're nearly at Wegovy's maintenance phase where monthly budgeting becomes predictable. Mounjaro's dual GIP+GLP-1 mechanism may require different dosing to achieve similar satiety effects compared to Wegovy's singular GLP-1 approach. EverydayMeds offers both medications through the same streamlined process, allowing direct monthly cost comparison based on your prescribed doses. Your prescriber can guide whether continuing Wegovy's proven escalation path or switching to Mounjaro's dual-action approach offers better value for your specific circumstances and weight management goals.
Wegovy vs Mounjaro Pricing: Complete Monthly Cost Breakdown
EverydayMeds provides transparent pricing for both Wegovy 1.7mg and Mounjaro options, with returning customers using DOSE25 at checkout to maintain optimal pricing. Wegovy 1.7mg costs £139.99 monthly, progressing to £209.99 for the 2.4mg maintenance dose from week 17 onwards. Our Elevate Duo bundle (1.7mg + 2.4mg) costs £369.99, providing seamless transition from your current dose to maintenance with Reliable Supply continuity. The Consistency 1.7mg bundle offers two pens for £309.99, ideal if extending this dose phase under prescriber guidance.
Mounjaro pricing varies by prescribed dose strength, with each pen providing a month's supply regardless of the milligram strength selected by your prescriber. The 1.7mg Wegovy to Mounjaro cost comparison requires knowing your target Mounjaro dose, as the dual-action mechanism may achieve comparable effects at different dose points. Both medications qualify for new customer FIRST40 pricing or returning customer DOSE25 discounts, ensuring consistent access to the best available rates. Annual budgeting becomes straightforward once you reach maintenance dosing, whether continuing with Wegovy 2.4mg or transitioning to an appropriate Mounjaro maintenance level.
Clinical Evidence Supporting 1.7mg Wegovy to Mounjaro Decisions
The STEP trial programme demonstrates that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, with dose escalation through 1.7mg being crucial for optimal efficacy (Wilding et al., NEJM, 2021). The 1.7mg dose represents weeks 13-16 where many patients experience accelerated results as they approach the 2.4mg maintenance level. Clinical trials show this escalation phase as essential for building tolerance whilst maximising weight management benefits.
Mounjaro's SURMOUNT trials demonstrate the dual GIP+GLP-1 mechanism's efficacy, though direct comparison between 1.7mg Wegovy to Mounjaro outcomes isn't appropriate due to different trial designs and patient populations. Both medications require prescription-only access with ongoing clinical monitoring to ensure safety and efficacy. Your prescriber's assessment of your response to 1.7mg Wegovy will inform whether continuing escalation or switching to Mounjaro's dual-action approach offers the most appropriate clinical pathway for your individual circumstances.
How Wegovy 1.7mg Works vs Mounjaro's Dual Mechanism
Wegovy 1.7mg contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. At the 1.7mg dose level, most patients experience significant appetite reduction and may notice reduced food cravings as the medication works on brain appetite centres. The once-weekly injection maintains steady blood levels throughout the week, providing consistent appetite management between doses. This mechanism becomes increasingly effective as you progress through dose escalation, with 1.7mg representing near-optimal GLP-1 receptor activation. The approach focuses on single-pathway appetite regulation that has demonstrated robust clinical outcomes across the STEP trial programme.
Ordering Process: Wegovy 1.7mg or Mounjaro from EverydayMeds
Both Wegovy 1.7mg and Mounjaro require identical ordering processes through our GPhC-registered online pharmacy (#9012878), starting with a 3-minute clinical assessment covering your medical history, current medications, and weight management goals. Our prescribers review applications within 3 working days (or 24 hours with express service), determining whether Wegovy continuation or Mounjaro initiation suits your clinical profile. Once approved, both medications ship via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements essential for medication stability. The assessment specifically addresses your experience with 1.7mg Wegovy to inform appropriate Mounjaro dosing if switching medications. Payment processing includes automatic application of DOSE25 for returning customers, ensuring transparent pricing without hidden fees or subscription commitments.
Storage Advantages: 1.7mg Wegovy to Mounjaro Practical Considerations
Wegovy 1.7mg offers significant practical advantages over Mounjaro regarding storage flexibility, remaining stable for 6 weeks at room temperature below 30°C once removed from refrigeration compared to Mounjaro's 21-day limit. This makes Wegovy particularly suitable for frequent travellers or those with limited refrigeration access, reducing medication waste from temperature excursions. Both medications use pre-filled FlexTouch pens requiring refrigerated storage at 2-8°C before first use, with clear expiry labelling for safety monitoring. The 1.7mg Wegovy dose delivers precisely measured medication through the pen's dial mechanism, whilst Mounjaro pens provide similar precision for their respective dose strengths. Storage flexibility becomes increasingly important as you progress to maintenance dosing, where consistent weekly administration determines long-term success regardless of travel or lifestyle demands.
Week 13-16 Decision Point: Continuing Wegovy vs Switching to Mounjaro
The 1.7mg Wegovy phase represents a crucial decision window where patients often evaluate their medication response and consider alternative approaches like Mounjaro. Many patients experience their most significant appetite reduction during weeks 13-16, making this an ideal time to assess whether Wegovy's single GLP-1 pathway provides sufficient benefit or whether Mounjaro's dual mechanism might offer advantages. Cost considerations become paramount as you approach maintenance dosing, where monthly expenses continue indefinitely rather than the temporary escalation phase investments.
Switching from 1.7mg Wegovy to Mounjaro requires careful prescriber guidance to determine appropriate starting doses and avoid potential side effects from mechanism differences. Some patients find Mounjaro's dual-action approach provides better glucose control alongside weight management, whilst others prefer Wegovy's established single-pathway reliability. The monthly cost difference may favour one option over time, particularly when considering long-term maintenance phase expenses and your individual insurance or budget constraints.
Secure Your 1.7mg Wegovy Supply or Explore Mounjaro Options
EverydayMeds maintains consistent stock levels for both Wegovy 1.7mg and Mounjaro options, ensuring uninterrupted treatment regardless of your chosen pathway. Returning customers automatically qualify for DOSE25 pricing when ordering through https://everydaymeds.co.uk/products/wegovy-1-7mg, maintaining the £139.99 monthly cost for continued Wegovy therapy. Our clinical team provides ongoing support whether you're progressing to 2.4mg Wegovy maintenance or transitioning to Mounjaro under prescriber guidance. The decision between continuing 1.7mg Wegovy escalation or exploring Mounjaro alternatives should always involve your prescriber's clinical assessment of your individual response patterns. Both medications represent significant investments in your long-term health, supported by our GPhC-registered pharmacy's commitment to safe, reliable prescription-only medicine access alongside reduced-calorie diet and increased physical activity programmes.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
